Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Melanoma treatment details. Biologic therapy. Chemotherapy. Abramson Cancer Center at the University of Pennsylvania , Philadelphia, PA, United States

Survival: 10.5 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: United States
City/State/Province: Philadelphia, PA
Hospital: Abramson Cancer Center at the University of Pennsylvania
Journal: Link
Date: 12/2009

Patients: This phase 2 study involved 167 patients with metastatic melanoma. The median age was 61, ranging from 26 to 84 years of age. Most (69%) of the patients were men.

Treatment: Patients were treated with the chemotherapy drug temozolomide and the biological therapy sorafenib. Patients were divided into four different treatment groups. They all received the same drugs, but different doses/amounts, depending on whether or not they had brain metastases and previously had received treatment with temozolomide.

Toxicity: The most common grade 3 and 4 toxicity was lymphopenia. Other grade 3 and 4 toxicities included fatigue, hand/foot syndrome, diarrhea, rash, nausea, stomatitis, vomiting, and weight loss.

Results: The median overall survival was 10.5 months for patients that did not have brain metastases and did not previously receive treatment with temozolomide. The median overall survival was 5 months for patients previously treated with temozolomide (some of these patients also had brain metastases). The median overall survival for patients with brain metastases but no previous temozolomide was 8 months.

Correspondence: Dr. Keith T. Flaherty

E-mail to a Friend Email Physician More Information